Aged, Anemia, Hemoglobins
Conditions
Keywords
Anemia, Subcutaneous injection, PROCRIT, Erythropoietin, Epoetin Alfa, Hemoglobin Level, Elderly
Brief summary
The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo
Detailed description
Some elderly patients have a chronic condition that causes anemia (reduction in hemoglobin level, or low red cell count). Anemia occurs commonly with aging and is a frequent medical condition in individuals over the age of 65. Physical performance and function is generally worse in individuals who are anemic. This is a randomized, double-blind, placebo-controlled, multi-center study to assess physical function (to include falls) and fatigue in approximately 80 elderly patients with chronic anemia (anemia present for at least 3 months) and who are receiving weekly PROCRIT. The study will also evaluate hemoglobin levels (oxygen carrying protein in red blood cells), safety, fatigue and cognitive function. The study hypothesis is to demonstrate the study drug will be more effective in treatment of chronic anemia than placebo, resulting in the improvement of physical function and subsequent disabilities, generally well-tolerated. The patients will receive weekly injections of Epoetin alfa (PROCRIT®) or placebo at a starting dose of 10,000 units administered subcutaneously (under the skin).
Interventions
DRUGepoetin alfa
Sponsors
Ortho Biotech Products, L.P.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a history of chronic anemia defined as a documented Hb value of \<= 11.0 g/dL * No active cancer * At least 65 years of age with life expectancy of \> 6 months * Community dwelling patients * Patients with a Short Physical Performance (SPPB) Summary Score of 4-10 at screening and baseline * Patients with an Mini Mental State Examination (MMSE) score \>= 24
Exclusion criteria
* Positive stool guaiac test * Diagnosis of multiple myeloma and/or MGUS * History of venous thromboembolytic disease * Previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin recently * Uncontrolled or severe cardiovascular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the change in physical function from baseline to end of study as measured by the Short Physical Performance Battery (SPPB) summary score. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess efficacy of PROCRIT by achieving a target Hb of 12.5-12.9 g/dL;Change in FACT-An score;Change in Six-Minute Walk Test,Safety (Adverse Event Incidents, Lab Tests and Vital Signs);Cognitive function; Number and type of injuries from falls | — |
Outcome results
None listed